Apoptosis-regulating machinery

The apoptosis-regulating machinery refers to the integrated network of molecular components that execute programmed cell death (PCD), a fundamental biological process essential for development and tissue homeostasis [1]. This machinery is primarily categorized into the intrinsic pathway, which is controlled by the Bcl-2 family of proteins at the mitochondria, and the extrinsic pathway, which is triggered by the binding of ligands to cell surface death receptors like Fas or TNFR1 [2]. Both pathways converge on the activation of caspases, specialized cysteine proteases that cleave specific cellular substrates to bring about the morphological changes associated with apoptosis [3]. In many cancers, this machinery is suppressed through the overexpression of anti-apoptotic proteins like Bcl-2 or the loss of pro-apoptotic factors like p53, allowing malignant cells to survive despite DNA damage [4]. Conversely, overactivation of apoptotic pathways is linked to the loss of neurons in diseases such as Alzheimer's and Parkinson's [5]. Pharmacological intervention aims to either reactivate these pathways in oncology—exemplified by the Bcl-2 inhibitor Venetoclax—or inhibit them in degenerative or ischemic conditions [6]. Sources: [1] Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495-516. [2] NIH National Cancer Institute. Apoptosis. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/apoptosis. [3] Fuchs Y, Steller H. Programmed cell death in animal development and disease. Cell. 2011;147(4):742-758. [4] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. [5] Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol. 2000;1(2):120-129. [6] Ashkenazi A, et al. From basic apoptosis discoveries to advanced selective cancer therapies. Nat Rev Drug Discov. 2017;16(4):273-284.

Other names

Programmed cell death pathwayApoptotic signaling cascadeCell death machineryApoptosome complex componentsBcl-2 family regulatory network

Drugs targeting this machinery typically act by inhibiting anti-apoptotic proteins (e.g., Bcl-2, Bcl-xL) to lower the threshold for cell death, mimicking pro-apoptotic BH3-only proteins (BH3 mimetics), or modulating the activity of caspases to either induce apoptosis in malignant cells or prevent it in degenerative conditions [6].